SLAMF1 as a Risk Biomarker for Nontraumatic SAH: Evidence From a Multiomics Study
Our combined analytical approach identified SLAMF1 as a protein associated with increased SAH risk. SLAMF1, a receptor involved in modulating innate and adaptive immune responses, has been implicated in inflammatory and autoimmune diseases. SLAMF1 and related proteins represent promising biomarkers for SAH risk, potentially enhancing risk stratification, guiding preventive strategies, and informing future therapeutic development. Further research is necessary to explore its mechanistic role in SAH development.
Authors
- Lauren Hachmann Sansing (ORCID: https://orcid.org/0000-0002-6898-1680)
- Murat Günel (ORCID: https://orcid.org/0000-0002-2290-7055)
- Cyprien A. Rivier (ORCID: https://orcid.org/0000-0002-1148-1829)
- Andrew B. Koo (ORCID: https://orcid.org/0000-0002-2854-649X)
- Guido J. Falcone (ORCID: https://orcid.org/0000-0002-6407-0302)
- Kevin Navin Sheth (ORCID: https://orcid.org/0000-0003-2003-5473)
- Daniela Renedo (ORCID: https://orcid.org/0000-0003-4120-6649)
- Santiago Clocchiatti‐Tuozzo (ORCID: https://orcid.org/0000-0001-5377-434X)
- Ryan Hebert (ORCID: https://orcid.org/0000-0003-0492-6364)
- Nanthiya Sujijantarat (ORCID: https://orcid.org/0000-0002-5857-5718)
- Shufan Huo (ORCID: https://orcid.org/0000-0002-0119-7517)
- Julián Acosta (ORCID: https://orcid.org/0000-0001-6497-5454)
- Charles Matouk (ORCID: https://orcid.org/0000-0003-3234-9541)
Institutions
- Harvard University (US)
- Yale University (US)
- Anna Needs Neuroblastoma Answers (US)
- Norwegian Womens Public Health Association (NO)
Publication Details
- Journal
- Stroke
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1161/strokeaha.125.052604
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.00